73 related articles for article (PubMed ID: 7787398)
1. [Effect of shenmai injection on sIL-2R NK and LAK cells in patients with advanced carcinoma].
Feng PF; Liu LM; Shen YY
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1995 Feb; 15(2):87-9. PubMed ID: 7787398
[TBL] [Abstract][Full Text] [Related]
2. [Effects of Shenmai injection on immune function in stomach cancer patients after chemotherapy].
Lin SY; Liu LM; Wu LC
Zhongguo Zhong Xi Yi Jie He Za Zhi; 1995 Aug; 15(8):451-3. PubMed ID: 8580688
[TBL] [Abstract][Full Text] [Related]
3. [Some immune functions of patients with carcinoma].
Huang JS; Liu WW; Fang DC
Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):415-8. PubMed ID: 7720494
[TBL] [Abstract][Full Text] [Related]
4. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
5. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
6. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
[TBL] [Abstract][Full Text] [Related]
7. [Dynamic studies of NK activity, IL-2 production and sIL-2R expression in primary hepatic carcinoma patients before and after operation].
Cao YY
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):111-3. PubMed ID: 8223118
[TBL] [Abstract][Full Text] [Related]
8. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes.
Yokose N; Ogata K; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Leuk Res; 1994 Oct; 18(10):777-82. PubMed ID: 7934136
[TBL] [Abstract][Full Text] [Related]
10. [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
Cao GW; Yang WG; Du P
Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):428-31. PubMed ID: 7720497
[TBL] [Abstract][Full Text] [Related]
11. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
12. Influence of autologous blood transfusion on natural killer and lymphokine-activated killer cell activities in cancer surgery.
Heiss MM; Fasol-Merten K; Allgayer H; Ströhlein MA; Tarabichi A; Wallner S; Eissner HI; Jauch KW; Schildberg FW
Vox Sang; 1997; 73(4):237-45. PubMed ID: 9407641
[TBL] [Abstract][Full Text] [Related]
13. [A study of lymphokine-activated killer cells (LAK) activity of the peripheral blood from patients with gastric cancer].
Wang JB; Tan Y; Song GP
Zhonghua Nei Ke Za Zhi; 1990 Sep; 29(9):550-2, 576. PubMed ID: 2086030
[TBL] [Abstract][Full Text] [Related]
14. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
16. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
17. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin.
Shau H; Kim A; Golub SH
J Leukoc Biol; 1992 Apr; 51(4):343-9. PubMed ID: 1564398
[TBL] [Abstract][Full Text] [Related]
18. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging.
Chakraborty A; Chakraborty NG; Chattopadhyay U
Int J Cancer; 1996 Mar; 66(1):65-9. PubMed ID: 8608969
[TBL] [Abstract][Full Text] [Related]
19. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL
Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous lymphokine activated killer (LAK) activity in bronchoalveolar lavage cells from patients with bronchogenic carcinoma.
Stein-Streilein J; Guffee J; Ramos M; Pitchenik AE
Reg Immunol; 1989; 2(6):370-5. PubMed ID: 2485685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
